Imunon (NASDAQ:IMNN) Issues Earnings Results

Imunon (NASDAQ:IMNN) issued its quarterly earnings results on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.33, FiscalAI reports.

Here are the key takeaways from Imunon’s conference call:

• OVATION 3 enrollment is ahead of plan, with approximately 0.5 patients per site per month versus the planned 0.3 and historical rates of about 0.2. Imunon said 35% of planned sites are active or being activated and that it remains on track for its enrollment timeline.
• IMNN-001 continues to show encouraging efficacy and safety signals. In the Phase II OVATION 2 study, median overall survival was 45.1 months versus 30.4 months for control, while the company reported no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events.
• Preliminary data from the small Phase II MRD study showed lower minimal residual disease positivity with IMNN-001 than control, 44% versus 67%, alongside higher circulating tumor DNA clearance and rates of no evidence of disease. The trial remains ongoing, and statistical significance is uncertain because it was not powered primarily for that outcome.
• Imunon ended the quarter with $6.9 million in cash and said its current resources support operations only through year-end, despite reducing quarterly operating cash use to $3.0 million. Management acknowledged that additional capital will be needed to fully fund OVATION 3 and general administrative expenses.
• The company completed a financing of up to $10 million using non-convertible preferred stock and secured promissory notes with no warrants, which management said was structured to limit dilution and financing overhang. It also highlighted a 20% year-over-year decline in general and administrative expenses.

Imunon Stock Performance

Shares of IMNN opened at $1.61 on Thursday. The business’s 50-day moving average price is $1.80 and its 200 day moving average price is $2.54. The stock has a market capitalization of $6.77 million, a P/E ratio of -0.42 and a beta of 1.97. Imunon has a 1-year low of $1.47 and a 1-year high of $7.21.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Imunon stock. DRW Securities LLC lifted its position in Imunon, Inc. (NASDAQ:IMNN) by 6.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 58,830 shares of the company’s stock after acquiring an additional 3,803 shares during the period. DRW Securities LLC owned about 1.92% of Imunon worth $224,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a report on Friday, July 17th. Maxim Group set a $10.00 price target on shares of Imunon and gave the company a “buy” rating in a report on Friday, April 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.